<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814229</url>
  </required_header>
  <id_info>
    <org_study_id>UHL 08162</org_study_id>
    <secondary_id>REC 6794</secondary_id>
    <nct_id>NCT00814229</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Influenza H9 Vaccine in Humans</brief_title>
  <official_title>Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Biological Standards and Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals, Leicester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      H9N2 influenza circulates in animal and poultry and has caused delf limiting infections in
      children. Influenza H9N2 poses a pandemic threat to humans.

      This study evaluates the safety and immunogenicity of adjuvanted and non-adjuvanted whole
      virus and virosomal H9N2 vaccines by the intramuscular route. We also assess intradermal
      route of administration to see if this has any advantages. The aim is to assess antibody
      responses before and after vaccination. The hypothesis is that lower doses of adjuvanted
      vaccine will induce similar antibody responses to non-adjuvanted vaccine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, single centre comparative study in which fourteen groups of 40 male and
      female adults &gt;18 years of age will be randomly allocated to receive 1.7, 5, 15 or 45 Âµg
      quantities of whole virion (WV), Aluminium -adjuvanted WV(Al-WV), and virosomal (V) influenza
      A/Hong Kong/1073/99 (H9N2) vaccines by intramuscular injection into the deltoid muscle; or 5
      or 15microg WV vaccine administered by intradermal injection. A second dose of the same
      vaccine containing the same quantity of antigen as in the first dose will be administered 21
      days later. Subjects will be observed for local and systemic reactions for 30 minutes after
      each immunisation (day 0 and 21), and will be monitored for any reactions and other adverse
      events for 7 days after immunisation. Blood for immunogenicity studies will be obtained at
      day 0 (pre-immunisation), day-21 (+4 days), and at day-42 (i.e., 21 +4 days after the second
      immunization). Immunogenicity will be evaluated by haemagglutination inhibition, virus
      neutralization,, single radial haemolysis, neuraminidase inhibition and cellular mediated
      responses (in a subset of 5-10 subjects from each group).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean antibody titres of antibody to influenza H9 by HI and neutralising antibody assays</measure>
    <time_frame>Pre vaccination, 21 days and 42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactogenicity of influenza H9 vaccine</measure>
    <time_frame>within 7 days of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroprotective antibody titres to influenza H9 by HI and neutralising antibody</measure>
    <time_frame>pre vacciantion, 21 and 42 days post-vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Vaccine 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 11</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>vaccine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine vaccine, IM, 15microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, alum, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus, alum, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 vaccine, whole virus, alum, IM, 15 microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 vaccine, whole virus, alum, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosome vaccine, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 15microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, ID, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection</description>
    <arm_group_label>Vaccine 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, ID, 15microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection</description>
    <arm_group_label>Vaccine 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mentally competent adults, who have signed an informed consent form after having
             received a detailed explanation of the study protocol.

          -  Male or female subjects over 18 years who are either healthy or have a stable medical
             condition.

          -  Able to understand and comply with all study procedures and to complete study diaries

          -  Individuals who can be contacted throughout the study and are available for all study
             visits

          -  Females should either be using secure contraceptive precautions including a) the oral
             contraceptive pill, b) condom/barrier contraception c) partner has had a vasectomy, d)
             be surgically sterilised, or e) post- (defined as at least two years since the last
             menstrual period)

        Exclusion Criteria:

          -  Any clinically significant concurrent illness or unstable medical condition including:
             malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or
             progressive renal or hepatic pathology, chronic obstructive pulmonary disease
             requiring oxygen therapy, and any active neurological disorder.

          -  Individuals with a history of anaphylaxis or serious reactions to vaccines;
             hypersensitivity to eggs, chicken protein, chicken feathers, influenzal viral protein,
             neomycin or polymixin, or products containing mercury.

          -  Persons with known immunosuppressive disease or who use systemic immunosuppressive
             drugs or other drugs listed in section 8 of the British National Formulary (BNF) or
             chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF
             to suppress a chronic disease process, or have received in the last 6 months
             radiotherapy or chemotherapy.

          -  Subjects who are at high risk of developing illnesses of the immune system.

          -  Individuals who are taking immunostimulant therapy or interferon

          -  Individuals who have received blood products or immunoglobulins parenterally during
             the preceding three months.

          -  Women should not be pregnant or lactating.

          -  Women who refuse to use a reliable contraceptive method throughout the study

          -  Known or suspected drug abuse.

          -  Individuals who have received another vaccine or experimental (investigational) drug
             in the preceding 4 weeks.

          -  Individuals who have previously received H9N2 vaccine

          -  Unable to lead an independent life either physically or mentally

          -  Regularly drink more than 40 units of alcohol weekly

          -  Individuals who have had acute respiratory pathology or infections requiring systemic
             antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic
             therapy for prevention of urinary tract infections is acceptable).

          -  Individuals who had a temperature over 38 degrees C in the preceding 3 days.

          -  Individuals who, in the opinion of the investigator, have conditions that might
             complicate interpretation of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl G Nicholson, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leicester</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Profressor Karl Nicholson</name_title>
    <organization>University of Leicester</organization>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>H9N2</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

